Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8174001 | 1.00 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DHRH1MGLL | |
| SCHEMBL5662288 | 1.00 | ADRA1A (0.42) | ADRA1AADRA1BADRA1DHRH1MGLL | |
| SCHEMBL7995847 | 0.87 | MGLL (0.39) | MGLLGAAKDM1A | |
| SCHEMBL7747880 | 0.87 | MGLL (0.39) | MGLLGAAKDM1A | |
| SCHEMBL7747876 | 0.87 | MGLL (0.39) | MGLLGAAKDM1A | |
| SCHEMBL7972575 | 0.86 | MGLL (0.39) | MGLLGAACYP1A2CYP2D6FAAH | |
| SCHEMBL7225595 | 0.85 | MGLL (0.41) | ADRA1AADRA1BADRA1DHRH1MGLL | |
| SCHEMBL8173301 | 0.85 | MGLL (0.43) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL7966161 | 0.85 | MGLL (0.43) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL6222781 | 0.81 | MGLL (0.38) | MGLLGAACYP1A2CYP2D6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2004-02-26 | — | — | US | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-04-24 | — | — | US | disclosed |
| US-6410554-B1 | ADRENERGIC ANTAGONIST | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| WO-2000027816-A1 | OXAZOLIDINONES USEFUL AS ALPHA 1A ADRENOCEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-05-18 | — | — | WO | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999048530-A1 | COMBINATION THERAPY FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 224/4885ADRA1B 306/4885ADRA1D 247/4885 |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | ADRA1A 46/4885ADRA1B 56/4885ADRA1D 48/4885 |
| US-20040038855-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 88/4885ADRA1B 143/4885ADRA1D 100/4885 |
| US-20030077701-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | ADRA1A 224/4885ADRA1B 306/4885ADRA1D 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.